-
July 27, 2011
There’s been a continual shift to defensive, income-oriented shares since the second quarter, and these three ...
-
July 27, 2011
Here are four drug stocks investors should watch heading into the second-half of the week.
-
July 26, 2011
Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
-
June 26, 2011
Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the ...
-
June 22, 2011
Merck is set up to exceed low-ball estimates.
-
June 07, 2011
Investors shouldn't be spooked by the normal post-ASCO sell-off
-
May 06, 2011
Four stocks that are holding up well during a short-term market pullback.
-
May 03, 2011
Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
-
April 20, 2011
Lilly isn't dynamic, but the value is there.
-
April 13, 2011
These two decent dividend-paying stocks are more attractive than they may seem on the surface.
-
January 31, 2011
There's little growth to excite pharma investors, but there is more value here than some realize.
-
December 16, 2010
Novartis closes the deal for Alcon.
-
October 26, 2010
Savient's inability to sell itself puts almost everything about the company's value in flux.
-
October 14, 2010
Pfizer does a deal that is good, but not great.
-
September 16, 2010
Obtaining FDA approval is only part of the story for this one-drug company.
-
September 10, 2010
Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
-
September 01, 2010
Sanofi has decided to make its intentions public and ratchet up the pressure on GENZ management.
-
August 27, 2010
Investors should keep an eye on how much drug companies rely on its top sellers.
-
August 26, 2010
In good times more risk can be taken. But for now, let's look at a couple of companies paying shareholders a healthy ...
-
August 17, 2010
If you own a stock that's contemplating a spinoff, consider the possibility that the new entity rather than the ...
